Symbol="ARGX"
AssetType="Common Stock"
Name="argenx NV ADR"
Description="argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands."
CIK="1697862"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="29596754000"
EBITDA="-430244000"
PERatio="None"
PEGRatio="0"
BookValue="2.043"
DividendPerShare="0"
DividendYield="0"
EPS="-7.05"
RevenuePerShareTTM="0.602"
ProfitMargin="-0.475"
OperatingMarginTTM="-0.635"
ReturnOnAssetsTTM="-0.103"
ReturnOnEquityTTM="-0.136"
RevenueTTM="835263000"
GrossProfitTTM="-251786000"
DilutedEPSTTM="-7.05"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="2.299"
AnalystTargetPrice="570.62"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="78.22"
PriceToBookRatio="7.24"
EVToRevenue="72.3"
EVToEBITDA="-21.25"
Beta="0.473"
num_52WeekHigh="550.76"
num_52WeekLow="333.07"
num_50DayMovingAverage="464.59"
num_200DayMovingAverage="401.82"
SharesOutstanding="58537000"
DividendDate="None"
ExDividendDate="None"
symbol="ARGX"
open="504.48"
high="505.21"
low="499.62"
price="502.49"
volume="161261.00"
latest_trading_day="2023-08-31"
previous_close="503.35"
change="-0.86"
change_percent="-0.1709%"
aroon_positive_momentum_days="90"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="90"
Volume_recent_avg="269296"
Change_recent_avg="0.4"
Delta_recent_avg="9.17"
Variance_recent_avg="4.59"
Change_ratio_recent_avg="0.08"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="90"
Aroon_momentum_negative="10"
image_negative_thumbnail_id_1="1157"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0191.jpeg"
image_negative_thumbnail_id_2="1094"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0127.jpeg"
image_neutral_thumbnail_id_1="553"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_neutral_thumbnail_id_2="575"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0024.jpeg"
image_positive_thumbnail_id_1="1013"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0175.jpeg"
image_positive_thumbnail_id_2="611"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0097.jpeg"
image_professor_thumbnail_id_1="1198"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
